Dr. William Schuyler Jones, of the Duke Clinical Research Institute, Durham, North Carolina, discusses the ADAPTABLE trial with Dr. Ron Waksman. The study, which was presented as a late-breaking trial at ACC.21 Virtual, found no difference in a composite outcome of death, myocardial infarction or stroke between patients assigned to a low dose (81 mg) vs. a high dose (325 mg) of aspirin with a median 26-month follow-up. Of interest was that patients were recruited and randomized remotely, with no in-person study visits, which helped the investigators recruit 15,000 patients during the COVID-19-related restrictions on travel and office visits.